HULIO Drug Profile
Summary for Tradename: HULIO
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for HULIO Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for HULIO Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for HULIO Derived from Patent Text Search
No patents found based on company disclosures
HULIO Market Dynamics, Biosimilar Competition, Patent Position and Financial Trajectory
Hulio is a biosimilar of AbbVie’s Humira, with adalimumab-fkjp as its active ingredient in the United States. Fujifilm Kyowa Kirin Biologics developed Hulio, while Viatris commercializes it in major markets. The product entered the U.S. market in 2023 after Humira’s principal U.S. exclusivity period ended. Its commercial outlook depends on price competition, payer formulary access, pharmacy substitution rules, manufacturing scale and Viatris’s ability to compete with multiple adalimumab biosimilars.
Hulio has an established European presence and U.S. FDA approval, but public sources do not disclose standalone Hulio revenue. Viatris reports company-level and portfolio-level financial results rather than product-specific Hulio sales. The product’s financial trajectory is therefore best assessed through market access, biosimilar pricing, competitive entry and Viatris’s overall biosimilars strategy.
What is Hulio and who markets it?
Hulio is a tumor necrosis factor inhibitor biosimilar to Humira. Its active ingredient is adalimumab-fkjp in the U.S. and adalimumab in European regulatory nomenclature.
| Item | Hulio profile |
|---|---|
| Reference product | Humira, adalimumab |
| Developer | Fujifilm Kyowa Kirin Biologics |
| U.S. commercial partner | Viatris |
| U.S. product name | Hulio |
| U.S. nonproprietary name | Adalimumab-fkjp |
| Regulatory pathway | FDA 351(k) biosimilar application |
| U.S. FDA approval | 2023 |
| Interchangeability | Not designated interchangeable in the United States |
| European approval | European Union approval in 2018 |
| Major therapeutic areas | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and other immune-mediated diseases |
The European Commission authorized Hulio in October 2018. The European Medicines Agency concluded that Hulio was highly similar to Humira and that its benefits and risks were comparable for the approved indications (European Medicines Agency, 2018).
The U.S. Food and Drug Administration approved Hulio as a biosimilar to Humira in 2023. The FDA approval did not give Hulio interchangeable status. That distinction affects automatic pharmacy substitution and can materially influence uptake in the retail and specialty pharmacy channels (U.S. Food and Drug Administration, 2023).
When did Hulio lose exclusivity barriers and enter the U.S. market?
Hulio entered the U.S. market after AbbVie’s negotiated settlement framework allowed adalimumab biosimilars to launch in 2023. Humira maintained a dominant U.S. position until the end of its exclusivity period, despite the FDA approving several adalimumab biosimilars before commercial launch.
The key U.S. timing milestones were:
| Date | Event |
|---|---|
| 2018 | European Commission authorized Hulio |
| 2018 | Mylan and AbbVie settlement arrangements supported a future U.S. adalimumab biosimilar launch |
| January 2023 | First U.S. adalimumab biosimilars launched |
| 2023 | FDA approved Hulio |
| July 2023 | Hulio became commercially available in the U.S. market |
| 2023 onward | Multiple adalimumab biosimilars competed with Humira and each other |
The commercial entry date was more important than FDA approval alone. Biosimilar applicants could obtain regulatory approval while remaining blocked from marketing under patent settlements. This created a staggered launch market in which the FDA approval count exceeded the number of products available to patients.
What patents protect Hulio and Humira?
Hulio does not rely on a conventional small-molecule patent estate. Its protection comes primarily from biologics manufacturing know-how, cell-line development, analytical characterization, process controls, formulation work and regulatory exclusivity.
Humira’s relevant patent barriers included composition, formulation, dosing and manufacturing patents. AbbVie disclosed an extensive patent portfolio around adalimumab and used that portfolio to negotiate launch settlements with biosimilar developers. The core Humira composition patent expired years before the first U.S. biosimilar launches, but later patents and settlement agreements delayed market entry.
For Hulio, the critical patent questions are different:
- Whether Viatris or Fujifilm Kyowa Kirin owns or licenses manufacturing patents.
- Whether production processes can be replicated at commercial scale.
- Whether formulation and device patents restrict presentation changes.
- Whether regional patent rights affect supply from particular manufacturing sites.
- Whether future litigation concerns manufacturing methods rather than the active molecule.
Does Hulio have Orange Book-listed patents?
No. Biologic products are generally not listed in the FDA Orange Book in the same manner as approved small-molecule drugs. The FDA’s Purple Book is the relevant database for licensed biological products and biosimilars.
Hulio’s competitive position must therefore be analyzed through its biologics license, biosimilar designation, patent litigation and settlement history rather than an Orange Book patent listing. The Humira reference product and its patent settlements remain commercially relevant, but Hulio does not receive an Orange Book exclusivity position.
How many companies compete with Hulio?
Hulio competes with Humira and a large group of FDA-approved or regionally approved adalimumab biosimilars. U.S. competitors include products associated with Amgen, Boehringer Ingelheim, Sandoz, Samsung Bioepis, Celltrion, Pfizer and Coherus.
Major U.S. adalimumab biosimilars include:
| Company | Biosimilar brand or product | Commercial position |
|---|---|---|
| Amgen | Amjevita | First U.S. launch in January 2023 |
| Boehringer Ingelheim | Cyltezo | Interchangeable designation |
| Sandoz | Hyrimoz | Broad biosimilar commercialization |
| Samsung Bioepis | Hadlima | U.S. and international competition |
| Celltrion | Yuflyma | High-concentration adalimumab competition |
| Pfizer | Abrilada | U.S. adalimumab biosimilar |
| Coherus | Yusimry | Lower-cost commercial strategy |
| Viatris/Fujifilm Kyowa Kirin | Hulio | U.S. and European competition |
The most important competitive divide is not only between Humira and biosimilars. It is also between low-concentration and high-concentration presentations, citrate-free formulations, autoinjectors, interchangeable products and payer-specific net pricing.
How strong is the Hulio patent estate?
Hulio’s patent position is commercially moderate rather than dominant. The product has the regulatory protection associated with a biosimilar approval, but it does not control the adalimumab market through broad composition patents.
Its competitive defenses are more likely to come from:
- Manufacturing complexity.
- Regulatory approval across multiple jurisdictions.
- Supply reliability.
- Device and presentation rights.
- Customer contracts and payer access.
- Viatris’s distribution infrastructure.
- Fujifilm Kyowa Kirin’s biologics production capabilities.
Manufacturing barriers are meaningful. Adalimumab is a monoclonal antibody requiring controlled cell culture, purification, viral clearance, analytical comparability and batch consistency. A competitor may obtain a biosimilar approval but still struggle to achieve competitive cost of goods or uninterrupted supply.
Hulio’s weakness is the absence of a distinctive U.S. interchangeability advantage. Products with interchangeable status can receive automatic substitution under applicable state pharmacy laws and payer arrangements. Hulio must therefore compete through contracting, physician confidence, specialty pharmacy access and supply performance.
What is the FDA regulatory status of Hulio?
Hulio is FDA-approved as a biosimilar to Humira. Biosimilarity means that the product is highly similar to the reference biologic, with no clinically meaningful differences in safety, purity and potency. FDA biosimilarity does not automatically establish interchangeability.
The FDA approval covers multiple inflammatory and autoimmune conditions aligned with Humira’s approved indications. The regulatory designation allows Hulio to compete clinically across a broad market, including rheumatology, gastroenterology, dermatology and ophthalmology.
Hulio’s principal regulatory limitations are commercial rather than clinical:
- It does not have U.S. interchangeable status.
- Pharmacy substitution depends on state law and payer policy.
- Physicians may need to prescribe or approve the product.
- Specialty pharmacy systems may prioritize other adalimumab products.
- Contracting can produce different net prices across insurers.
What patent litigation and settlement agreements affect Hulio?
The central legal event was the settlement structure between AbbVie and adalimumab biosimilar developers. These agreements allowed biosimilar launches after specified dates without requiring each developer to litigate every asserted patent through trial.
A 351(k) biosimilar applicant does not use a conventional Paragraph IV certification under the Hatch-Waxman framework. Instead, the applicant may participate in the biologics patent dance, provide notice of commercial marketing and challenge reference-product patents under the Biologics Price Competition and Innovation Act.
Hulio’s U.S. entry was shaped by this framework and by settlement timing. The settlement environment reduced the probability of an immediate injunction against commercial launch while preserving AbbVie’s ability to assert patents and negotiate launch dates. Publicly available information does not establish a Hulio-specific damages judgment or a court finding that would materially restrict its current commercial presence.
What are the main market dynamics for Hulio?
The U.S. adalimumab market is moving from single-brand dominance to multi-product contracting. The leading market forces are:
Net-price competition
List-price reductions do not fully measure biosimilar competition. Manufacturers may offer rebates, discounts and patient-support programs to secure formulary placement. The product with the lowest net cost can differ from the product with the lowest published list price.
Formulary control
Large insurers and pharmacy benefit managers can determine whether patients remain on Humira, transition to a biosimilar or receive a preferred biosimilar. A product without interchangeability may still gain volume through plan-level policies and physician-directed switching.
High-concentration formulations
The market has shifted toward citrate-free, high-concentration formulations that reduce injection volume and improve patient convenience. Hulio must compete against products with newer presentations and established autoinjector platforms.
Specialty pharmacy distribution
Adalimumab is a specialty product. Distribution, prior authorization support, copay assistance and refill coordination affect actual utilization. Viatris’s established commercial infrastructure is a competitive advantage, but it does not eliminate the need for payer contracting.
Physician switching
Rheumatologists, gastroenterologists and dermatologists may be more willing to initiate biosimilars in treatment-naive patients than to switch stable patients. Payer mandates can accelerate switching, while clinical continuity and patient preference can slow it.
What is Hulio’s financial trajectory?
Hulio’s standalone revenue is not publicly reported by Viatris or Fujifilm Kyowa Kirin. Viatris includes Hulio within broader product and biosimilars reporting. The public record therefore supports a directional assessment rather than a product-level revenue forecast.
Hulio’s financial trajectory has four phases:
| Phase | Financial effect |
|---|---|
| Pre-launch | Development, regulatory and manufacturing investment with no U.S. product revenue |
| Initial launch | Rapid access to a large market, but heavy discounting and launch costs |
| Competitive expansion | Volume growth offset by price erosion from multiple biosimilars |
| Mature market | Lower per-unit revenue, with profitability dependent on scale and manufacturing efficiency |
Viatris reported total company revenue of approximately $15.4 billion for 2023, but that figure does not isolate Hulio revenue (Viatris, 2024). The company’s biosimilars portfolio provides strategic value through recurring specialty sales and global commercial reach. Hulio’s contribution is likely to be measured more by portfolio scale, manufacturing utilization and payer access than by premium pricing.
The most likely financial pattern is volume growth combined with declining net price. Early entrants often secure better payer positions, while later entrants may need deeper discounts. Hulio entered after several adalimumab biosimilars, limiting its ability to capture first-mover economics in the U.S.
European economics are structurally different. Biosimilar uptake is generally more advanced, but national tender systems and reference pricing can drive aggressive price reductions. Hulio’s European presence gives Viatris and Fujifilm Kyowa Kirin experience in biosimilar commercialization, though European volume does not guarantee high margins.
What generic and biosimilar launch risks exist for Hulio?
Hulio faces biosimilar competition rather than generic competition. The main risks are:
- Formulary exclusion by major payers.
- Price compression from multiple adalimumab competitors.
- Preference for interchangeable products.
- Loss of share to high-concentration formulations.
- Manufacturing interruptions.
- Physician resistance to switching.
- Patient-support differences.
- Regional tender losses.
- Newer biologics competing with adalimumab therapy.
- Patent disputes involving devices, formulations or manufacturing processes.
The risk of an immediate generic-style substitution shock is lower because biologics operate under more complex substitution and contracting rules. The risk of sustained price erosion is higher because Humira was one of the largest biologic markets in the world and attracted many biosimilar entrants.
How does Hulio compare with Humira and competing adalimumab biosimilars?
| Factor | Hulio | Humira | Interchangeable adalimumab biosimilar |
|---|---|---|---|
| Product type | Biosimilar | Reference biologic | Biosimilar |
| U.S. market status | Approved and launched | Mature reference product | Approved and potentially substitutable |
| Price position | Discounted relative to Humira | Historically premium | Often aggressive |
| Interchangeability | No U.S. designation | Not applicable | May have substitution advantage |
| Patent dependence | Manufacturing and regulatory position | Extensive historical patent estate | Manufacturing plus settlement position |
| Commercial strength | Viatris distribution and global experience | AbbVie brand recognition and contracts | Substitution and payer advantages |
| Main risk | Crowded biosimilar market | Loss of share and price erosion | Margin compression |
Hulio’s strongest advantages are regulatory approval, global experience and Viatris’s commercial infrastructure. Its principal disadvantages are late entry into a crowded U.S. market and the lack of interchangeable designation.
What is the outlook for Hulio revenue and market share?
Hulio is likely to produce a declining-price, scale-dependent revenue profile. U.S. sales can grow even while average selling prices fall if Viatris wins sufficient prescription volume. Profitability will depend on:
- Manufacturing cost per unit.
- Contracting discipline.
- Share of high-concentration presentations.
- Payer coverage.
- European tender performance.
- Supply reliability.
- Cross-selling through Viatris’s specialty portfolio.
Hulio is unlikely to recreate Humira’s historical revenue economics. Its commercial role is closer to a portfolio anchor in biosimilars than a high-margin protected product. The largest value drivers are recurring volume, production scale and access to payer channels.
Key Takeaways
- Hulio is adalimumab-fkjp, a biosimilar to Humira developed by Fujifilm Kyowa Kirin Biologics and commercialized by Viatris.
- The product received European approval in 2018 and entered the U.S. market in 2023.
- Hulio is FDA-approved but does not have U.S. interchangeable status.
- Hulio is not an Orange Book-listed small-molecule product; the FDA Purple Book and biologics patent framework are more relevant.
- Its market is defined by payer contracting, specialty pharmacy access, high-concentration formulations and intense price competition.
- Public disclosures do not provide standalone Hulio revenue.
- The expected financial trajectory is volume expansion with lower net prices and declining margins as more adalimumab biosimilars compete.
- Manufacturing scale, supply reliability and formulary access are more important to Hulio’s economics than a broad composition-patent estate.
FAQs
Is Hulio the same as Humira?
Hulio is not the same branded product as Humira. It is a biosimilar containing adalimumab-fkjp and is highly similar to Humira, with no clinically meaningful differences under the FDA biosimilar standard.
Can pharmacists automatically substitute Hulio for Humira?
Automatic substitution is not universally permitted. Hulio does not have FDA interchangeable status, so substitution depends on state law, payer policy and prescriber authorization.
Is Hulio available for Crohn’s disease and ulcerative colitis?
Yes. FDA approval covers multiple Humira-aligned inflammatory conditions, including Crohn’s disease and ulcerative colitis, subject to the product label and local prescribing requirements.
Does Hulio have a separate patent expiration date?
Hulio does not depend on a single composition patent in the manner of a small-molecule drug. Its commercial protection depends on regulatory approval, manufacturing know-how, formulation and device rights, and the expiration or enforcement of relevant third-party patents.
Will Hulio revenue increase as Humira sales decline?
Hulio has an opportunity to gain volume as Humira loses share, but its revenue will be constrained by competition from other adalimumab biosimilars and aggressive payer discounting. Volume growth does not necessarily translate into higher revenue or margin.
References
-
European Medicines Agency. (2018). Hulio: EPAR - product information. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (2023). Hulio (adalimumab-fkjp) prescribing information and biosimilar approval materials. https://www.fda.gov/
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Viatris Inc. (2024). 2023 annual report. https://investor.viatris.com/
-
AbbVie Inc. (2024). 2023 annual report. https://investors.abbvie.com/
More… ↓
